Atlas Trials

Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC

Clinical trial NCT04265872 · RECRUITING

Trial details

NCT number
NCT04265872
Sponsor
Baylor Research Institute
Status
RECRUITING
Phase
Early Phase 1
Study type
INTERVENTIONAL
Breast Cancer
Start date
2020-10-15
Primary completion
2026-12-31
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.